News | December 26, 2007

GE Healthcare Expands Nuclear Cardiology Portfolio

December 27, 2007 - GE Healthcare announced today that it has entered into an agreement with DRAXIMAGE, a division of DRAXIS Health Inc. of Montreal, Canada, to become the exclusive distributor of DRAXIMAGE Sestamibi upon its approval by the FDA and the expiration of the primary innovator patent.

An abbreviated New Drug Application (ANDA) for DRAXIMAGE Sestamibi was submitted by DRAXIMAGE to the FDA in February 2007, and is currently under review.

“We are delighted to announce this agreement, and continue to expand our portfolio of diagnostic imaging products through our North American radiopharmacy network,” said John Chiminski, president & CEO of GE Healthcare’s Medical Diagnostics division. “Our expertise in nuclear cardiology as the innovator of Myoview makes us ideally suited to make this new product available through our Radiopharmacy Operation that has the highest standards in the industry.”

Technetium-labeled radiopharmaceuticals, which include Myoview (Kit for the Preparation of Technetium Tc99m Tetrofosmin for Injection), are used in approximately 90 percent of nuclear medicine studies performed to detect coronary artery disease. Over eight million patients receive myocardial perfusion imaging each year, as the increasing rates of obesity, diabetes, and hypertension (heart failure) continue to contribute to disease progression. According to the American Heart Association, coronary artery disease is responsible for more than half of the deaths associated with cardiovascular diseases (2006).

“Nuclear cardiology is a proven technology, and we’re confident that our partnership with DRAXIMAGE will expand the access to and applicability of these procedures when and where they are needed. This agreement further demonstrates our commitment to Nuclear Medicine, through outstanding Radiopharmacy performance and the broadest product portfolio in the industry,” Chiminski added.

For more information: www.gehealthcare.com and www.draximage.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init